As of close of business last night, Chromadex Corp’s stock clocked out at $3.84, up 1.32% from its previous closing price of $3.79. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 628500 shares were traded.
Ratios:
To gain a deeper understanding of CDXC’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 41.97. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.09.
On August 11, 2022, B. Riley Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $2.40.
On March 08, 2022, ROTH Capital started tracking the stock assigning a Buy rating and target price of $7.ROTH Capital initiated its Buy rating on March 08, 2022, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’23 when Gerber Brianna bought 5,000 shares for $1.41 per share. The transaction valued at 7,050 led to the insider holds 27,436 shares of the business.
Jaksch Frank L Jr bought 7,000 shares of CDXC for $11,830 on Jun 12 ’23. The Director now owns 231,339 shares after completing the transaction at $1.69 per share. On May 31 ’23, another insider, Fried Robert N, who serves as the Chief Executive Officer of the company, bought 7,000 shares for $1.42 each. As a result, the insider paid 9,940 and bolstered with 95,001 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDXC now has a Market Capitalization of 289.19M and an Enterprise Value of 265.29M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.46 while its Price-to-Book (P/B) ratio in mrq is 10.12. Its current Enterprise Value per Revenue stands at 3.17 whereas that against EBITDA is -68.13.
Stock Price History:
The Beta on a monthly basis for CDXC is 1.96, which has changed by 141.51% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, CDXC has reached a high of $4.06, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is 1.8500, while the 200-Day Moving Average is calculated to be 1.5826.
Shares Statistics:
It appears that CDXC traded 199.78K shares on average per day over the past three months and 857.1k shares per day over the past ten days. A total of 74.98M shares are outstanding, with a floating share count of 44.60M. Insiders hold about 40.77% of the company’s shares, while institutions hold 15.50% stake in the company. Shares short for CDXC as of Feb 29, 2024 were 1.21M with a Short Ratio of 6.06, compared to 1.3M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.61% and a Short% of Float of 2.19%.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.02 for the current quarter, with a high estimate of -$0.01 and a low estimate of -$0.03, while EPS last year was -$0.03. The consensus estimate for the next quarter is -$0.01, with high estimates of $0 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.01 and -$0.03 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.05, with 3 analysts recommending between $0.09 and $0.03.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $23.97M. It ranges from a high estimate of $24.41M to a low estimate of $23.7M. As of the current estimate, Chromadex Corp’s year-ago sales were $22.56M, an estimated increase of 6.30% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for CDXC’s current fiscal year. The highest revenue estimate was $98.6M, while the lowest revenue estimate was $97.02M, resulting in an average revenue estimate of $97.57M. In the same quarter a year ago, actual revenue was $83.57M, up 16.80% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $114.37M in the next fiscal year. The high estimate is $116.5M and the low estimate is $112.2M. The average revenue growth estimate for next year is up 17.20% from the average revenue estimate for this year.
